Hologic, Inc. (NASDAQ:HOLX) Position Lessened by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 17.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 197,058 shares of the medical equipment provider’s stock after selling 40,593 shares during the quarter. Russell Investments Group Ltd.’s holdings in Hologic were worth $14,074,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of HOLX. Qube Research & Technologies Ltd raised its holdings in shares of Hologic by 117.2% during the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock worth $95,651,000 after acquiring an additional 743,557 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of Hologic in the fourth quarter worth about $30,079,000. Assenagon Asset Management S.A. lifted its position in shares of Hologic by 90.4% in the third quarter. Assenagon Asset Management S.A. now owns 845,493 shares of the medical equipment provider’s stock worth $58,677,000 after buying an additional 401,486 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Hologic by 8.9% in the third quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock worth $335,763,000 after buying an additional 393,371 shares during the last quarter. Finally, Clearbridge Investments LLC acquired a new stake in shares of Hologic in the third quarter worth about $25,398,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HOLX. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. UBS Group boosted their price target on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Raymond James boosted their price target on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. JPMorgan Chase & Co. lifted their price objective on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Friday. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $84.56.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Trading Up 0.8 %

HOLX stock opened at $76.54 on Friday. The firm has a market cap of $17.97 billion, a P/E ratio of 36.27, a P/E/G ratio of 2.58 and a beta of 1.01. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $86.74. The business’s 50 day moving average is $76.12 and its 200-day moving average is $72.97.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 12.98%. Hologic’s revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.06 EPS. Equities analysts anticipate that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.